ASH 2022
Bispecific antibodies - consolidating data, clinical implications & combinational aspects
Magnetismm-3, MajesTEC-2, GO39775
ASH 2022
Bispecific antibodies - consolidating data, clinical…
GMMG-Concept, UK OPTIMUM/MUKnine Trial, Myeloma XI, RADAR UK-MRA Myeloma XV
ASH 2022
Treatment of high-risk NDMM patients and MRD-driven…
CC-98633-MM-001, Atalanta-1, KarMMa-2 Cohort 2a, CARTITUDE-2 Cohort B, CC‑95266‑MM‑001
ASH 2022
CAR-T cells - manufacturing, earlier lines & new…
Ascent Trial, GEM-CESAR
ASH 2022
Asymptomatic myeloma - what do we really want to…
ELM-2, FLIPI24
ASH 2022
When to treat or not? Watch and wait!? Bispecifics or…
Alycante, ZUMA-7
ASH 2022
Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV…
ALPINE, BRUIN
ASH 2022
Zanu with superior PFS, Pirtobrutinib Update in R/R…
TRIANGLE, TARMAC
ASH 2022
Do we treat all MCL identically? New data on Ibru,…
ASH 2022
NDMM highlights
GMMG-Concept
ASH 2022
Quadruplet for newly diagnosed high-risk patients
DSMM XIII
ASH 2022
To transplant or not?
Myeloma XI
ASH 2022
Maintenance with lenalidomide - how long?
MRD2STOP, GEM2014MAIN, RADAR
ASH 2022
Establish MRI diagnostics early
ASH 2022
NDMM highlights
GMMG-Concept
ASH 2022
Isa-KRd bei HR NDMM: Hohe MRD Negativität
MRD2STOP, GEM2014MAIN, RADAR
ASH 2022
MRD-Diagnostik früh etablieren
Myeloma XI
ASH 2022
Erhaltung mit Lenalidomid - wie lange?
IFM2017-03
ASH 2022
Kortikoid-Einsparung bei unfitten Patienten unter DR
ASH 2022
Bispecific antibodies highlights
Nex-T CAR-T
ASH 2022
New generation CAR-T cell therapy with fast…
MonumenTAL-1
ASH 2022
Still biting, Talquetamab?
GO39775
ASH 2022
Bispecific antibodies
MajesTEC-2, KarMMa-2 Cohort 2a
ASH 2022
The future of immunotherapy
ASH 2022
More treatment options with bispecifics emerging!
NEX-T CAR-T, Atalanta-1
ASH 2022
New CAR-T technologies
MonumenTAL-1
ASH 2022
GPRC5D-immunotherapy
ASH 2022
CAR-T cells: new targets and early treatment
ASH 2022
Bispecific antibodies highlights
Nex-T CAR-T
ASH 2022
Neue Generation der CAR-T Zelltherapie mit schneller…
GO39775
ASH 2022
Bispesifikke antistoffer
MonumenTAL-1
ASH 2022
GPRC5D immunterapi
NEX-T CAR-T, Atalanta-1
ASH 2022
Nye CAR-T-teknologier
ASH 2022
Bispezifische Antikörper: Weitere Behandlungsoptionen…
MajesTEC-2, KarMMa-2 Cohort 2a
ASH 2022
Die Zukunft der Immuntherapie
ASH 2022
CAR-T Zellen: Neue erfolgsversprechende Targets und…
GEM-CESAR, ASCENT
ASH 2022
Smouldering myeloma - potentially curable?
ASH 2022
Plasma cells aren't alone!
GEM-CESAR, ASCENT
ASH 2022
Smouldering Myelom – potentiell heilbar?
Triangle
ASH 2022
TRIANGLE - addition of Ibrutinib will improve outcome…
VALERIA
ASH 2022
VALERIA response-adapted treatment for R/R MCL patients
Tarmac
ASH 2022
Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib…
Triangle
ASH 2022
Ibrutinib + Ctx replaces autologous stem cell…
ASH 2022
Glofitamab in R/R mantle cell lymphoma
ASH 2022
Fixed-duration Glofitamab produces high quality and…
ASH 2022
The R2-Acalabrutinib combination in first-line is…
ASH 2022
Glofitamab demonstrates high efficacy in r/r MCL
Triangle
ASH 2022
Ibrutinib added in induction and maintenance improves…
Triangle
ASH 2022
Ibrutinib combined with chemotherapy could replace ASCT
VALERIA
ASH 2022
Valeria- responsstyrd behandling för recidiverande MCL
Triangle
ASH 2022
TRIANGLE- tillägg av ibrutinib förbättrar…
ASH 2022
Glofitamab för recidiverande MCL
Tarmac
ASH 2022
El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib…
ASh 2022
Glofitamab en esquema fijo de 12 meses produce…
Triangle
ASH 2022
Ibrutinib en inducción y mantenimiento mejora la…
ASH 2022
El triplete R2-Acalabrutinib en primera línea es…
Triangle
ASH 2022
Ibrutinib + Ctx ersetzt autologe…
ASH 2022
Watch and Wait remains standard of care
ASH 2022
Is watch & wait still valualble in follicular lymphoma?
EPCORE NHL-2 arm 2b
ASH 2022
Bispecific antibody Epcoritamab s.c. + R2 convincing
Elara Trial
ASH 2022
Tisagenlecleucel at r/r FL: convincing response more…
FLIPI24
ASH 2022
A new FLIPI to predict POD24 in follicular lymphoma
EPCORE NHL-2 arm 2b
ASH 2022
Epcoritamab - bispecific antibody highly effective in…
ELM-2
ASH 2022
Odronextamab in relapsed/refractory follicular lymphoma
ASH 2022
Watch and Wait bleibt Standard
EPCORE NHL-2 arm 2b
ASH 2022
Epcoritamab-R2 nel linfoma follicolare…
FLIPI24
ASH 2022
Un nuovo FLIPI per predire la POD24 nel linfoma…
Elara Trial
ASH 2022
Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen…
EPCORE NHL-2 arm 2b
ASH 2022
Bispezifischer Antikörper Epcoritamab s.c. + R2…
ELM-2
ASH 2022
Odronextamab nel linfoma follicolare…
ASH 2022
E' ancora valido il watch & wait nel linfoma…
Alycante
ASH 2022
Alycante - axi-cel in transplant-ineligible R/R DLBCL…
Alycante
ASH 2022
Two highlight studies in DLBCL treatment
Alycante
ASH 2022
Alycante - axi-cel till patienter med tidigt recidiv av…
Alycante
ASH 2022
Deux études marquantes dans le traitement du DLBCL
ASH 2022
Ventricular arrhythmias under combination ibrutinib +…
ASH 2022
Ventrikuläre Arrhythmien unter Kombi Ibrutinib +…
ALPINE
ASH 2022
Zanubrutinib demonstrates superiority in r/r CLL/SLL
BRUIN
ASH 2022
Pirtobrutinib shows activity in pre-treated r/r…
Neutrodiet
ASH 2022
Is it time to feed our patients?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!